 NESS ZIONA, Israel--BUSINESS WIRE--BiomX Inc. NYSE American: PHGE, a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced positive results of a first-in-human Phase 1a pharmacokinetic study of BX002. BX002 is BiomXs orally administered phage therapy candidate targeting Klebsiella pneumoniae K. pneumoniae bacteria in the gut, which have been linked to the pathogenesis of both inflammatory bowel disease IBD and 